Bit Index AI  | Broadcast Live   |   Upload & Publish  | About  | Register  | Sign in
Remember me on this computer
You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.


Close [ X ]
Copy this code to embed & stream this video on your website
Copy this URL to share or create a link back to this video
Dr. Christoph Uherek
Head of Preclinical Development
Biotest AG: BT-062 - A Potent Antibody-Drug Conjugate for the Treatment of CD138 Expressing Tumors
BT-062 is an antibody-drug conjugate binding to CD138, which is over-expressed on multiple myeloma (MM) and a variety of solid tumors. BT-062 has shown good tolerability in clinical phase I/II studies and achieved clinical benefit in MM patients. Additionally, BT-062 demonstrated very good efficacy in solid tumor animal models (e.g. triple negative breast cancer), making it a promising candidate for development in solid tumor indications.

[ close ] 
Please select the appropriate option to comply with legal regulations

Individual Investor Professional Investor or Financial Advisor
This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only. This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.
I comply with these terms I comply with these terms
Remember my choice for all channels on this portal Enter Media Channel »
No reliance should be placed on the information on this site which may change without notice.
You should read the Terms & Conditions section before browsing this site.

Search in Sort By
1 2 3 4 of 4   MORE   SHOW
  Select a title or search in slides to skip chapters
Biotest AG, BT-062: A Potent Antibody-Drug Conjugate for the Treatment of CD138 Expressing Tumors
Biotest Group, Headquarters, Subsidiaries, Employees, Biotest shares, Financials, Biotest Group
Plasma Proteins, Biotherapeutics, Immunoglobulins, Hyper- Immunoglobulins, Clotting factors, Human Albumin, Monoclonal Antibodies, BT 061, BT 062, BT 063, Clinical Development, Production at BPC, License Agreement , Biotest: a specialized pharmaceutical company
Multiple Myeloma, Forecast, hematologic malignancy , Multiple Myeloma: Overview
Myeloma Current Treatment, Stem cell transplant candidates, Thalidomide, dexamethasone 1, Velcade, dexamethasone, Velcade, doxorubicin, dexamethasone, Thalomid, Velcade, liposomal doxorubicin, Revlimid, dexamethasone, Drugs in clinical development , Multiple Myeloma: Current Treatment Overview
Efficacy Issues, drug toxicities, multiple myeloma, The Most Significant Unmet Needs in Multiple Myeloma Arise from Safety and Efficacy Issues
Multiple Myeloma Market, Novel Agents, Revlimid, Velcade, Thalomid, Multiple Myeloma Market (7MM)1 - Growth Driven by Increased Uptake of 'Novel Agents'
BT-062 Market Opportunity, Relapsed, Refractory, BT-062 , BT-062 Market Opportunity in Relapsed, Refractory Multiple Myeloma
potent Antibody-Drug Conjugate, Multiple Myeloma, Tumor-targeting, CD138, BT-062: A potent Antibody-Drug Conjugate for Treatment of Multiple Myeloma
BT-062, Mode of Action, Binding, Internalization, Binding to CD138, Receptor, polymerization , BT-062: Mode of Action
Conjugate Optimization, Efficacy, BT-062-mediated, Xenograft model, toxin-linker, BT-062: Improved Efficacy after Conjugate Optimization
Clinical Development, Monotherapy, Revlimid, Result , BT-062: Clinical Development in Multiple Myeloma
Study 969, Clinical Benefit, Monotherapy Study, , Study 969: Clinical Benefit Shown in a Dose Finding Phase I Multiple Myeloma Monotherapy Study
serum FLC, oligo-secretory Multiple Myeloma, , BT-062: Repeated Single Dose Study 969
Intensification of Exposure, Phase I/IIa, monotherapy, , Study 975: Intensification of Exposure by More Frequent Dosing - Study Ongoing
Rationale for Clinical Development, Solid Tumor Indications, CD138 expression, mammary, prostate, lung, head and neck, bladder, and pancreatic carcinoma, clinical study, BT-062: Rationale for Clinical Development in Solid Tumor Indications
BT-062 in Solid Tumor Indications, remission, carcinoma xenograft, HER2-negative, triple negative breast cancer, BT-062 in Solid Tumor Indications
BT-062: Development Plan and Milestones, Mono therapy, Combination therapy, Efficacy, BT-062: Development Plan and Milestones